Biomea Fusion (BMEA) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing two oral metabolic programs: icovamenib (menin inhibitor for diabetes) and BMF-650 (next-gen oral GLP-1 receptor agonist for obesity).

• Retains full worldwide rights and is funded through major clinical milestones into Q1 2027.

• Pipeline includes Phase II trials for icovamenib in type 2 diabetes and Phase I for BMF-650 in obesity.

Icovamenib: Mechanism, clinical data, and impact

• Targets menin to restore beta-cell mass, aiming to delay insulin dependence and reduce complications in diabetes.

• Demonstrated durable HbA1c reduction and increased C-peptide after a 12-week course, with effects lasting up to 52 weeks.

• Showed synergy with GLP-1 therapies, enhancing insulin secretion and beta-cell function.

• Favorable safety profile with no treatment-related serious adverse events and comparable adverse event rates to placebo.

• Ongoing Phase II studies target insulin-deficient and GLP-1 inadequate responder populations, with primary endpoint data expected in Q4 2026.

BMF-650: Next-generation oral GLP-1 RA

• Designed for improved oral bioavailability, higher plasma protein binding, and better tolerability.

• Demonstrated robust, dose-dependent weight loss (~15% in 28 days) in obese monkey models.

• Preclinical studies show greater oral exposure and lower variability compared to orforglipron.

• Phase I clinical study in obese volunteers is ongoing, with 28-day weight reduction data anticipated in Q2 2026.